The Day In Review: Pfizer Inc. And Teva Pharmaceutical Industries Limited Settle Generic Drug Lawsuits

November 21, 2006 -- Pfizer settled a patent dispute with Teva over a cancer medication and an antibiotic for $70 million; diabetes drug Byetta, from Lilly and Amylin won European approval; Immtech was granted Orphan Drug designation for a pneumonia drug; Prana raised $6 million to fund a Phase IIa trial of an Alzheimer’s drug; Repligen won Orphan Drug designation for RG1068, a synthetic human secretin; and Dyax completed the double-blind portion of its Phase III trial of DX-88, a treatment for hereditary angioedema. The Centient Biotech 200™ dropped 16 points lower to 3990, a loss of .41%. More details...